Alnylam Pharmaceuticals Inc (ALNY)
273.91
+7.32
(+2.75%)
USD |
NASDAQ |
Nov 01, 16:00
273.75
-0.16
(-0.06%)
After-Hours: 20:00
Alnylam Pharmaceuticals Enterprise Value: 33.57B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 33.57B |
| October 31, 2024 | 32.63B |
| October 30, 2024 | 34.55B |
| October 29, 2024 | 34.96B |
| October 28, 2024 | 35.25B |
| October 25, 2024 | 34.98B |
| October 24, 2024 | 36.08B |
| October 23, 2024 | 36.23B |
| October 22, 2024 | 36.44B |
| October 21, 2024 | 35.87B |
| October 18, 2024 | 36.37B |
| October 17, 2024 | 36.48B |
| October 16, 2024 | 36.97B |
| October 15, 2024 | 35.27B |
| October 14, 2024 | 34.75B |
| October 11, 2024 | 34.88B |
| October 10, 2024 | 34.14B |
| October 09, 2024 | 33.15B |
| October 08, 2024 | 33.18B |
| October 07, 2024 | 32.61B |
| October 04, 2024 | 32.77B |
| October 03, 2024 | 32.97B |
| October 02, 2024 | 33.23B |
| October 01, 2024 | 33.81B |
| September 30, 2024 | 33.68B |
| Date | Value |
|---|---|
| September 27, 2024 | 33.69B |
| September 26, 2024 | 33.65B |
| September 25, 2024 | 33.41B |
| September 24, 2024 | 33.19B |
| September 23, 2024 | 33.30B |
| September 20, 2024 | 33.56B |
| September 19, 2024 | 33.87B |
| September 18, 2024 | 33.47B |
| September 17, 2024 | 33.63B |
| September 16, 2024 | 33.11B |
| September 13, 2024 | 32.45B |
| September 12, 2024 | 32.00B |
| September 11, 2024 | 32.02B |
| September 10, 2024 | 31.29B |
| September 09, 2024 | 30.90B |
| September 06, 2024 | 30.08B |
| September 05, 2024 | 30.68B |
| September 04, 2024 | 30.90B |
| September 03, 2024 | 30.98B |
| August 30, 2024 | 32.12B |
| August 29, 2024 | 35.24B |
| August 28, 2024 | 34.43B |
| August 27, 2024 | 34.38B |
| August 26, 2024 | 32.95B |
| August 23, 2024 | 33.40B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
8.364B
Minimum
Nov 14 2019
36.97B
Maximum
Oct 16 2024
19.33B
Average
18.32B
Median
Nov 01 2023
Enterprise Value Benchmarks
| Pfizer Inc | 221.03B |
| Regeneron Pharmaceuticals Inc | 84.89B |
| BridgeBio Pharma Inc | 6.072B |
| Biomarin Pharmaceutical Inc | 12.36B |
| Johnson & Johnson | 400.99B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -111.57M |
| Revenue (Quarterly) | 500.92M |
| Total Expenses (Quarterly) | 577.82M |
| EPS Diluted (Quarterly) | -0.87 |
| Gross Profit Margin (Quarterly) | 82.85% |
| Profit Margin (Quarterly) | -22.27% |
| Earnings Yield | -0.96% |
| Normalized Earnings Yield | -0.6712 |